CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- Open-market buys, last 90 days
- $38,094
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$38,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-26 | Williams Timothy SVP & General Counsel | Grant or award · Employee Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2020-02-26 | Wijkstrom Joakim SVP, Chief Marketing Officer | Grant or award | +30,000 | 60,000 | ||
| 2020-02-26 | Wijkstrom Joakim SVP, Chief Marketing Officer | Grant or award · Employee Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2020-02-26 | Polymeropoulos Mihael Hristos President and CEO | Grant or award | +60,000 | 1,294,579 | ||
| 2020-02-26 | Polymeropoulos Mihael Hristos President and CEO | Grant or award · Employee Stock Option (Right to Buy) | +140,000 | 140,000 | ||
| 2020-02-26 | Jones Aranthan II Chief Corp. Affairs Officer | Grant or award | +30,000 | 90,000 | ||
| 2020-02-26 | Jones Aranthan II Chief Corp. Affairs Officer | Grant or award · Employee Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2020-02-26 | Birznieks Gunther SVP, Business Development | Grant or award | +30,000 | 177,231 | ||
| 2020-02-26 | Birznieks Gunther SVP, Business Development | Grant or award · Employee Stock Option (Right to Buy) | +70,000 | 70,000 | ||
| 2020-02-14 | Mitchell Stephen Ray Director | Grant or award · Stock Option (right to buy) | +35,000 | 35,000 | ||
| 2020-01-02 | Reverberi Gian Piero SVP & Chief Commercial Officer | Sale | −1,155 | $16.06 | $19K | 166,834 |
| 2020-01-02 | Polymeropoulos Mihael Hristos President and CEO | Sale | −9,467 | $16.00 | $151K | 1,234,579 |
| 2020-01-02 | Kelly James Patrick EVP & Chief Financial Officer | Sale | −4,020 | $15.94 | $64K | 205,726 |
| 2020-01-02 | Birznieks Gunther SVP, Business Development | Sale | −4,020 | $15.93 | $64K | 147,231 |
| 2019-12-12 | Polymeropoulos Mihael Hristos President and CEO | Option exercise | +85,801 | $10.65 | $914K | 1,314,082 |
| 2019-12-12 | Polymeropoulos Mihael Hristos President and CEO | Sale | −70,036 | $16.98 | $1.2M | 1,244,046 |
| 2019-12-12 | Polymeropoulos Mihael Hristos President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −85,801 | 0 | ||
| 2019-12-11 | Polymeropoulos Mihael Hristos President and CEO | Option exercise | +89,199 | $10.65 | $950K | 1,300,654 |
| 2019-12-11 | Polymeropoulos Mihael Hristos President and CEO | Sale | −72,373 | $16.92 | $1.2M | 1,228,281 |
| 2019-12-11 | Polymeropoulos Mihael Hristos President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −89,199 | 85,801 |
Page 15 of 20 · 387 trades